Kalios
← Stacks

Stack — Muscle & strength

GH Stack — CJC-1295 (no DAC) + Ipamorelin · Tested together in people: none published

Gray market

Checked · 19 sources · 9 corrections on this page · No vendors · No affiliates · No one buys a word of it

CJC-1295: FDA said no — its advisory panel voted against all five forms on December 4, 2024: 13 to 0, the acetate without DAC 12 to 1; Ipamorelin: FDA said no — on the do-not-compound list · legal line changed 18 Oct 2026 →

Sold as a research chemical. Some clinics and pharmacies still supply it; that’s their risk, not a change in the rule.

Built on: Growth Hormone Secretagogue Pair

The receipt

0 studies gave them to people together

Evidence on the combination
No data

None published

No study that gave them to people together is among the sources Kalios cites. Reports of people already taking both, registered trials, conference talks, patents and makers’ own tests don’t count.

What each does alone

Mechanism overlap · reasoning, not evidence

CJC-1295
Peptide — Growth Hormone Releasing Hormone (GHRH) Analog
Ipamorelin
Peptide — Selective Ghrelin Receptor Agonist (Growth Hormone Secretagogue)

Reasoning, not evidence: what each is described to do says nothing about what they do together.

References

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. (CJC-1295 DAC form; foundational pharmacology.)
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654.
  3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. (Ipamorelin discovery and selectivity.)
  4. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID: 10496658.
  5. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PMID: 16822960.
  6. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046908.
  7. Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I) by continuous GH-releasing peptide-2 infusion in older men and women. J Clin Endocrinol Metab. 2004;89(5):2290-2300. PMID: 15126555.
  8. Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-369. PMID: 9467542.
  9. Veldhuis JD, Bowers CY. Integrating GHS into the Ghrelin System. Int J Pept. 2010;2010:879503. PMID: 20798846.
  10. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
  11. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527.
  12. Johansen PB, Segard HB, Nedergaard L, Thorsted B, Raun K, Hansen BS. The growth hormone-releasing properties of ipamorelin compared to GHRP-6 in the conscious rat. Eur J Endocrinol. 1998;139:552-561. (Supportive preclinical selectivity data.)
  13. FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) — 503A / 503B Compounding. FDA.gov, updated 2025.
  14. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
  15. WADA. 2026 Prohibited List. Section S2 — peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency.
  16. Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. Metabolism. 1997;46(1):83-88. PMID: 9005975. (Six normal young volunteers: GH AUC 2,200.8 after hexarelin, 792.2 after GHRH, 4,259.2 after both, more than the arithmetic sum.)
  17. Tiulpakov AN, Brook CG, Pringle PJ, Peterkova VA, Volevodz NN, Bowers CY. GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clin Endocrinol (Oxf). 1995;43(3):347-350. PMID: 7586605. (Eight healthy men: the combined response did not differ from the sum of the separate ones.)
  18. Theratechnologies. EGRIFTA WR (tesamorelin) for injection, prescribing information (revised 03/2025). DailyMed set ID 839334d3-8c1d-4c26-9036-2ab524a6ea75 (version effective July 29, 2026). dailymed.nlm.nih.gov. Read October 3, 2026.
  19. Compounding submission to FDA: public comment with the 503A bulk drug substance nomination of CJC-1295 acetate and a practitioner monograph ("CJC 1295 v2"), Pharmacy Compounding Advisory Committee docket FDA-2024-N-4777, document FDA-2024-N-4777-0002, attachments 5 and 7, posted November 21, 2024. regulations.gov. Read October 4, 2026. (Compounded strengths and dosing of CJC-1295 with ipamorelin.)

See every change to this page → · Status now →

Checked 18 Oct 2026